

REMAP-CAP

IN THIS ISSUE

- Continuation of therapeutic dose heparin
- Ecraid webinar
- Weimar Sepsis Update
- Recruitment Update

Dear REMAP-CAP family,

Looking at the rain outside my window, I know autumn has now really started. This is typically a time for lots of hospitalizations for pneumonia, and we hope to contribute to finding better treatments for these patients in REMAP-CAP. We continue our COVID-19 domains, and have opened several new interventions for influenza. We are excited to transition to the European Clinical Trials regulation system over the next months, anticipate more results being published in the next weeks, and are organizing a variety of meetings online and face-to-face. You can read about REMAP-CAP and Ecraid in Weimar, and we will welcome you at ESICM LIVES in Milan in October too. We hope to meet you there!

On behalf of the REMAP-CAP team,
Lennie Derde



Publication - letter

Continuation of therapeutic dose heparin

COVID-19 infection promotes clots that block blood flow in small and large vessels which contributes to organ dysfunction, respiratory failure and death. In collaboration with ATTACC and ACTIV-4, REMAP-CAP has previously demonstrated that therapeutic dose heparin (a blood thinner) improves outcomes in hospitalised patients with COVID-19 if initiated when they are not critically ill. In contrast, if initiated when critically ill (in intensive care), it did not improve outcomes and may be harmful. However, there has been ongoing uncertainty what to do if a hospitalized patient (on therapeutic anticoagulation) becomes critically ill.

The recent data from REMAP-CAP published in Intensive Care medicine journal demonstrated that if a patient transitions from non-critically ill to critically ill, reducing heparin dose was likely better than continuing therapeutic dose heparin.

We are very thankful to all the patients who have contributed to REMAP-CAP as well as the hard work of many individuals from hospitals across the world. Read the full letter [here](#).

Ecraid webinar

Back in April we have organized an Ecraid Webinar to inform you about what being a part of Ecraid may mean for you. In case you missed the first webinar please be informed we are organizing another one, on the same topics: what Ecraid is and stands for, and what it means to be a part of the Ecraid network. This is also an opportunity for you to ask questions. The webinar will take place on October 3rd, 09:00-10:00 CEST (Amsterdam time). [Register here](#).

REMAP-CAP funding

For the last years, REMAP-CAP was funded via the H2020 Project "Rapid European COVID-19 Emergency Research response" (RECOVER). All sites with a contract with the UMC Utrecht have already been informed that this successful project has come to an end on August 13, 2023. UMC Utrecht and Ecraid are partner in the H2020 Project "European Clinical Research Alliance on Infectious Diseases" (ECRAID-Base) and have entered into a Grant Agreement, together with other organizations participating in this project, with the European Commission. REMAP-CAP will be continued in ECRAID-Base. ECRAID-Base is one of the projects of the Ecraid consortium. Should you have any further questions about ECRAID-Base or Ecraid, please reach out to the Project Manager of your country.

Recruitment Update

Worldwide

- 269 sites
- 12.826 unique patients
- 10.254 COVID-19 patients
- 22.485 randomisations

European Region

- 174 sites
- 7.465 unique patients
- 6.825 COVID-19 patients
- 14.079 randomisations

Since our last issue in May 2023 we added the following new sites to the REMAP-CAP family:

- Serbia: University Clinical Center of Serbia, Clinic for Pulmonary Diseases
- Israel: Beilinson Hospital-Rabin Medical Center
- Spain: University Hospital Marques de Valdecilla
- Spain: Hospital Regional Universitario de Málaga
- Italy: Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone"



Weimar Sepsis Update

The 11th Sepsis update took place from 6-8 September in Weimar, Germany. This hot topic congress was accompanied by extraordinarily hot weather. But inside it was cool and participants could focus on many interesting lectures and recent research and findings on sepsis. Lennie Derde gave a lecture about platform trials and the Ecraid organisation. At the Ecraid booth participants dropped by for more information about REMAP-CAP and Ecraid. They were really enthusiastic to join!

Happy recruiting! The REMAP-CAP Team

